O-GlcNAcylation-Inducing Treatments Inhibit Estrogen Receptor α Expression and Confer Resistance to 4-OH-Tamoxifen in Human Breast Cancer-Derived MCF-7 Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kanwal, Shahzina ^a,b   Fardini, Yann ^a,b   Pagesy, Patrick ^a,b   N'Tumba Byn, Thierry ^a,b   Pierre Eugène, Cécile ^a,b   Masson, Elodie ^a,b   Hampe, Cornelia ^a,b   Issad, Tarik ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBAMIC ACID DERIVATIVE; EARLY GROWTH RESPONSE FACTOR 1; ESTROGEN RECEPTOR ALPHA; GLUCOSAMINE; MESSENGER RNA; O LINKED N ACETYLGLUCOSAMINE TRANSFERASE; O(2 ACETAMIDO 2 DEOXY DEXTRO GLUCOPYRANOSYLIDENE)AMINO N PHENYLCARBAMATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN KINASE B; PROTEIN P21; SMALL INTERFERING RNA; SOMATOMEDIN C; TAMOXIFEN; TRANSFERASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOCATALYSIS; BIOSYNTHESIS; BREAST CANCER; CANCER CELL CULTURE; CELL PROTECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; EGR1 GENE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; O GLCNACYLATION; P21 GENE; PHOSPHOLIPID SYNTHESIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING;

ACETYLGLUCOSAMINE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOSYNTHETIC PATHWAYS; BREAST NEOPLASMS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEXOSAMINES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MCF-7 CELLS; OXIMES; PHENYLCARBAMATES; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84880065673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069150     Document Type: Article

References (64)

1. Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I, et al. (2009) Glucose avidity of carcinomas. Cancer Lett 276: 125-135. doi:10.1016/j.canlet.2008.08.007. PubMed: 18790562.
2. Dossus L, Kaaks R, (2008) Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab 22: 551-571. doi:10.1016/j.beem.2008.08.003. PubMed: 18971118.
3. Gillette CA, Zhu Z, Westerlind KC, Melby CL, Wolfe P, et al. (1997) Energy availability and mammary carcinogenesis: effects of calorie restriction and exercise. Carcinogenesis 18: 1183-1188. doi:10.1093/carcin/18.6.1183. PubMed: 9214601.
4. Dogan S, Hu X, Zhang Y, Maihle NJ, Grande JP, et al. (2007) Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res 9: R91. doi:10.1186/bcr1840. PubMed: 18162139.
5. Issad T, Masson E, Pagesy P, (2010) O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab 36: 423-435. doi:10.1016/j.diabet.2010.09.001. PubMed: 21074472.
6. Hanover JA, (2001) Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J 15: 1865-1876. doi:10.1096/fj.01-0094rev. PubMed: 11532966.
7. Hart GW, Housley MP, Slawson C, (2007) Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446: 1017-1022. doi:10.1038/nature05815. PubMed: 17460662.
8. Issad T, Kuo M, (2008) O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 19: 380-389. doi:10.1016/j.tem.2008.09.001. PubMed: 18929495.
9. Lefebvre T, Dehennaut V, Guinez C, Olivier S, Drougat L, et al. (2009) Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1800: 67-79. PubMed: 19732809.
10. Chou TY, Dang CV, Hart GW, (1995) Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A 92: 4417-4421. doi:10.1073/pnas.92.10.4417. PubMed: 7753821.
11. Chou TY, Hart GW, (2001) O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv Exp Med Biol 491: 413-418. doi:10.1007/978-1-4615-1267-7_26. PubMed: 14533811.
12. Lefebvre T, Pinte S, Guérardel C, Deltour S, Martin-Soudant N, et al. (2004) The tumor suppressor HIC1 (hypermethylated in cancer 1) is O-GlcNAc glycosylated. Eur J Biochem 271: 3843-3854. doi:10.1111/j.1432-1033.2004.04316.x. PubMed: 15373830.
13. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T, (2008) O-glycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. FEBS Lett 582: 829-834. doi:10.1016/j.febslet.2008.02.010. PubMed: 18280254.
14. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T, (2008) O-GlcNAc modification of FoxO1 increases its transcriptional activity: A role in the glucotoxicity phenomenon? Biochimie 90: 679-685. doi:10.1016/j.biochi.2008.03.005. PubMed: 18359296.
15. Olivier-Van Stichelen S, Guinez C, Mir AM, Perez-Cervera Y, Liu C, et al. (2011) The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of beta-catenin and cell proliferation. Am J Physiol Endocrinol Metab 302: E417-E424. PubMed: 22114026.
16. Mi W, Gu Y, Han C, Liu H, Fan Q, et al. (2011) O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta 1812: 514-519. doi:10.1016/j.bbadis.2011.01.009. PubMed: 21255644.
17. Krześlak A, Forma E, Bernaciak M, Romanowicz H, Bryś M, (2011) Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med, 12: 61-5. PubMed: 21567137.
18. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, et al. (2010) O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol, 29: 985-93. PubMed: 21461968.
19. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, et al. (2010) Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 29: 2831-2842. doi:10.1038/onc.2010.41. PubMed: 20190804.
20. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, et al. (2012) Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 287: 11070-11081. doi:10.1074/jbc.M111.302547. PubMed: 22275356.
21. Gu Y, Mi W, Ge Y, Liu H, Fan Q, et al. (2010) GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res 70: 6344-6351. doi:10.1158/0008-5472.CAN-09-1887. PubMed: 20610629.
22. Hurvitz SA, Pietras RJ, (2008) Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 113: 2385-2397. doi:10.1002/cncr.23875. PubMed: 18819158.
23. Pichard C, Plu-Bureau G, Neves ECM, Gompel A, (2008) Insulin resistance, obesity and breast cancer risk. Maturitas 60: 19-30. doi:10.1016/j.maturitas.2008.03.002. PubMed: 18485631.
24. Blanquart C, Karouri SE, Issad T, (2009) Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun 387: 748-753. doi:10.1016/j.bbrc.2009.07.105. PubMed: 19635455.
25. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, et al. (2012) Effect of insulin analogues on Insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLOS ONE 7(7):: e41992. doi:10.1371/journal.pone.0041992. PubMed: 22848683.
26. Lacasa D, Boute N, Issad T, (2005) Interaction of the insulin receptor with the receptor-like protein tyrosine phosphatases PTPalpha and PTPepsilon in living cells. Mol Pharmacol 67: 1206-1213. doi:10.1124/mol.104.009514. PubMed: 15630078.
27. Nouaille S, Blanquart C, Zilberfarb V, Boute N, Perdereau D, et al. (2006) Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 7: 512-518. PubMed: 16582879.
28. Blanquart C, Achi J, Issad T, (2008) Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem Pharmacol 76: 873-883. doi:10.1016/j.bcp.2008.07.027. PubMed: 18718450.
29. Boubekeur S, Boute N, Pagesy P, Zilberfarb V, Christeff N, et al. (2011) A new highly efficient substrate-trapping mutant of protein tyrosine phosphatase 1B (PTP1B) reveals full autoactivation of the insulin receptor precursor. J Biol Chem 286: 19373-19380. doi:10.1074/jbc.M111.222984. PubMed: 21487008.
30. Treilleux, Peloux N, Brown M, Sergeant A, (1997) Human estrogen receptor (ER) gene promoter-P1: estradiol-independent activity and estradiol inducibility in ER+ and ER- cells. Mol Endocrinol 11: 1319-1331. doi:10.1210/me.11.9.1319. PubMed: 9259322.
31. Liu JF, Issad T, Chevet E, Ledoux D, Courty J, et al. (1998) Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway. Eur J Biochem 258: 271-276. doi:10.1046/j.1432-1327.1998.2580271.x. PubMed: 9851716.
32. Strobel A, Siquier K, Zilberfarb V, Strosberg AD, Issad T, (1999) Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes. Diabetologia 42: 527-533. doi:10.1007/s001250051190. PubMed: 10333043.
33. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL, (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888. doi:10.1002/1097-0142(19801215)46:12+. PubMed: 7448733.
34. Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, et al. (2008) A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res 10: R88. doi:10.1186/bcr2158. PubMed: 18928543.
35. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, et al. (2011) Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 29: 4160-4167. doi:10.1200/JCO.2010.32.9615. PubMed: 21947828.
36. Kiang DT, Kollander RE, Thomas T, Kennedy BJ, (1989) Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49: 5312-5316. PubMed: 2766299.
37. Horwitz KB, McGuire WL, (1978) Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 253: 8185-8191. PubMed: 711743.
38. Laïos I, Journe F, Laurent G, Nonclercq D, Toillon RA, et al. (2003) Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 87: 207-221. doi:10.1016/j.jsbmb.2003.09.011. PubMed: 14672741.
39. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 97: 9042-9046. doi:10.1073/pnas.160016897. PubMed: 10908655.
40. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, et al. (1997) Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72: 102-109. doi:10.1002/(SICI)1097-0215(19970703)72:1. PubMed: 9212230.
41. Clark AS, West K, Streicher S, Dennis PA, (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717. PubMed: 12479367.
42. Kwei KA, Baker JB, Pelham RJ, (2012) Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLOS ONE 7: e46518. doi:10.1371/journal.pone.0046518. PubMed: 23029544.
43. Love DC, Hanover JA, (2005) The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci STKE: pp. 2005: re13.
44. Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, et al. (2008) Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab 295: E974-E980. doi:10.1152/ajpendo.90366.2008. PubMed: 18728220.
45. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, et al. (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451: 964-969. doi:10.1038/nature06668. PubMed: 18288188.
46. Nardelli GB, Lamaina V, Siliotti F, (1986) Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report). Eur J Gynaecol Oncol 7: 151-158. PubMed: 3536517.
47. Nardelli GB, Lamaina V, Marson S, Miola G, (1988) Receptor levels in breast cancer. Eur J Gynaecol Oncol 9: 54-58. PubMed: 3345786.
48. Zachara NE, Hart GW, (2004) O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta 1673: 13-28. doi:10.1016/j.bbagen.2004.03.016. PubMed: 15238246.
49. Kudlow JE, (2006) Post-translational modification by O-GlcNAc: another way to change protein function. J Cell Biochem 98: 1062-1075. doi:10.1002/jcb.20926. PubMed: 16598783.
50. Jackson SP, Tjian R, (1988) O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell 55: 125-133. doi:10.1016/0092-8674(88)90015-3. PubMed: 3139301.
51. deGraffenried LA, Hopp TA, Valente AJ, Clark RA, Fuqua SA, (2004) Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat 85: 111-120. doi:10.1023/B:BREA.0000025398.93829.78. PubMed: 15111769.
52. Roos MD, Su K, Baker JR, Kudlow JE, (1997) O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol 17: 6472-6480. PubMed: 9343410.
53. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, et al. (2001) O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci U S A 98: 6611-6616. doi:10.1073/pnas.111099998. PubMed: 11371615.
54. Lim K, Chang HI, (2009) O-GlcNAcylation of Sp1 interrupts Sp1 interaction with NF-Y. Biochem Biophys Res Commun 382: 593-597. doi:10.1016/j.bbrc.2009.03.075. PubMed: 19302979.
55. Lim K, Chang HI, (2009) O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription factors. Biochem Biophys Res Commun 380: 569-574. doi:10.1016/j.bbrc.2009.01.121. PubMed: 19285002.
56. Lim K, Chang HI, (2009) O-GlcNAc modification of Sp1 inhibits the functional interaction between Sp1 and Oct1. FEBS Lett 583: 512-520. doi:10.1016/j.febslet.2008.12.007. PubMed: 19070619.
57. Lim K, Chang HI, (2010) Elevated O-linked N-acetylglucosamine correlated with reduced Sp1 cooperative DNA binding with its collaborating factors in vivo. Biosci Biotechnol Biochem 74: 1668-1672. doi:10.1271/bbb.100289. PubMed: 20699577.
58. Lim K, Chang HI, (2010) O-GlcNAc inhibits interaction between Sp1 and sterol regulatory element binding protein 2. Biochem Biophys Res Commun 393: 314-318. doi:10.1016/j.bbrc.2010.01.128. PubMed: 20138838.
59. Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, et al. (2005) ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 280: 3185-3196. PubMed: 15557281.
60. Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, et al. (2005) Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma. Cancer 104: 925-930. doi:10.1002/cncr.21262. PubMed: 15999367.
61. Kim CG, Choi BH, Son SW, Yi SJ, Shin SY, et al. (2007) Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell Signal 19: 1290-1300. doi:10.1016/j.cellsig.2007.01.008. PubMed: 17307334.
62. Mandlekar S, Kong AN, (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477. doi:10.1023/A:1012437607881. PubMed: 11595837.
63. Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, et al. (2004) Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 145: 1302-1313. PubMed: 14645110.
64. Madeo A, Vinciguerra M, Lappano R, Galgani M, Gasperi-Campani A, et al. (2010) c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 29: 978-991. doi:10.1038/onc.2009.400. PubMed: 19935718.